CELGENE CORP /DE/ Form 8-K
March 29, 2019
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 29, 2019

**CELGENE CORPORATION** 

(Exact name of registrant as specified in its charter)

001-34912 **Delaware** 22-2711928 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 86 Morris Avenue, Summit, 07901 **New Jersey** (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (908) 673-9000 (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: "Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) "Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) "Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) "Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company " If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition

period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange Act. "

#### ITEM 8.01 OTHER EVENTS.

On March 29, 2019, Celgene Corporation ("*Celgene*") announced the settlement of litigation with Lotus Pharmaceutical Co., Ltd. and Alvogen Pine Brook, LLC relating to patents for REVLIMID® (lenalidomide).

Attached hereto and incorporated herein by reference as Exhibit 99.1 is the press release.

#### ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

d)Exhibits

99.1 Press Release dated March 29, 2019

2

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### **CELGENE CORPORATION**

Date: March 29, 2019 By: /s/ David V. Elkins

David V. Elkins

Executive Vice President Chief Financial Officer

(principal financial and accounting officer)

3